IRX5

Across TCGA pan-cancer cohorts, IRX5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IRX5 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IRX5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IRX5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where IRX5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.872	0.375	.007	10	view →
LSCC	DFS	Median	II,III,IV	0.214	0.932	.002	7	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.740	.031	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IRX5–LUAD (OS)

Open the LUAD breakdown →